Saturday, October 31, 2026

Clorox Company Stock Is 9% Up So Far Today

Clorox Company Stock Is 9% Up So Far Today

The Clorox Company (NYSE: CLX), a prominent player in the global market for consumer and professional products, has seen interesting market activity recently. Their shares experienced an unexpected boost, rising nearly 10% during early trading on Thursday morning. Despite this surge, however, they still trade significantly below their 52-week high levels, underscoring the unpredictability of these shares.

Clorox's Performance and Operations

Clorox operates across various sectors including Health and Wellness, Household, Lifestyle, and International segments. Recently, Clorox experienced a slow trading session, which paralleled with an overall decline on the NYSE index.

Profitability and Investment Returns

The company stands out in terms of profitability with a trailing twelve-month earnings per share of $4.61 and its price to earnings ratio standing at an eye-popping 274.91. This shows investors paying an exorbitant premium for future growth prospects. In addition, its return on equity stands at 22.46% over the past year, indicating strong shareholder return on investments made into Clorox's shares.

Stock Performance Against Moving Averages

The Clorox stock has demonstrated strong relative performance versus moving averages, surpassing both its 50-day and 200-day moving averages. This may signal an upward trend; however, market volatility should always be considered. During Q4, for instance, intraday variation reached 0.88%, showing susceptibility to market shifts.

Potential Return for Investors

Clorox offers investors who seek dividend yield an attractive potential return. Morningstar estimates the company's forward annual dividend yield at 3.04%; their next payment is expected on April 24th 2023.

Revenue Growth

Despite challenging market conditions, Clorox maintained strong annual revenue growth, marked by a 5.9% quarterly rise. This suggests that its diverse portfolio of products continues to generate income.

Future Considerations for Investors

Clorox's stock performance demonstrates its susceptibility to market fluctuations. Despite this exposure, its impressive portfolio, profitability, and revenue growth make it an enticing option for investors. Therefore, investors seeking long-term returns should carefully examine both its individual stock specifics as well as market trends before making their decisions.

More news about Clorox Company (CLX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com